Jyoti Mayadev, MD, discusses the clinical significance of tumor area positivityas a predictive biomarker in locally advanced cervical cancer.
Jyoti Mayadev, MD
Advertisement
Articles by Jyoti Mayadev, MD
Jyoti Mayadev, MD, discusses the value of ctDNA as a prognostic biomarker for relapse and survival in patients with locally advanced cervical cancer.
Jyoti Mayadev, MD, discusses the prognostic and predictive significance of ctDNA in locally advanced cervical cancer.
Jyoti Mayadev, MD, discusses the phase 1 NRG-GY017 trial evaluating atezolizumab given as an immune primer or concurrently with extended field chemoradiation in patients with locally advanced, node-positive cervical cancer.
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on OncLive
1
FDA Approval Tees Up T-DXd Plus Pertuzumab as a New SOC in HER2+ Breast Cancer
2
NALIRIFOX and FOLFIRINOX Facilitate Personalized Treatment in Metastatic Pancreatic Cancer
3
Iberdomide Plus Daratumumab/Dexamethasone Displays High Response Rates in NDMM
4
FDA Advises on Next Steps for Nogapendekin Alfa Inbakicept Plus BCG sBLA in BCG-Unresponsive Papillary NMIBC
5